The recent presidential mandate for a government-business task force gives senior leaders a chance to revisit pharma localisation strategy in South Africa. It reads like an industrial policy response, but it has direct consequences for health economics, market access and the long-term affordability of medicines. Teams working on pricing, reimbursement and system design now need to weigh short-term cost control against supply security and the sector’s domestic economic contribution.

A sector at the crossroads of cost and capacity

South Africa has the most developed pharmaceutical industry in Sub-Saharan Africa, with a market valued near USD 8 billion and close to 20 000 employees. Local manufacturers, and the wider industry that supplies more than 80 per cent of medicines, have watched their value share of major public tenders fall sharply over a decade. Antiretroviral contracts that once returned 72 per cent of value to local plants fell to 28 per cent, and solid-dose awards followed a similar path. More than 2 500 manufacturing jobs disappeared within eighteen months, and several facilities closed. Private-sector single exit price adjustments lagged both consumer inflation and input-cost rises, which squeezed margins further. Government maintains that volume awards to local producers have increased in selected categories and that patient affordability remains the non-negotiable priority. An existing Inter-Ministerial Committee and the newly opened CSIR FuturePharma platform both point to a parallel aim: rebuilding active-ingredient capability and pandemic readiness. The task force therefore has to resolve a conflict between pure price competition and keeping strategic manufacturing assets.

Redefining value beyond acquisition cost

The most important change a coherent pharma localisation strategy needs concerns how value is measured. Industry examples compare a locally made antiretroviral at a one-rand premium with a cheaper import. The saving on paper can be wiped out by lost domestic multipliers. Health economics teams need total-cost-of-ownership models that capture employment effects, skills retention, reduced stock-out risk and foreign-exchange exposure. Market access functions should prepare evidence that links verifiable local content to wider system effects, not unit price alone. Value-based pricing discussions in the task force’s private-sector work stream could reward investment and supply resilience instead of treating every manufacturer as interchangeable. Without this wider frame, reimbursement decisions will keep optimising the current year at the expense of capacity that National Health Insurance volumes will later require.

Pricing strategies and reimbursement decisions under pressure

Private pricing rules sit at the centre of the mandate. Single exit price increases below inflation have left manufacturers exposed to global cost movements while they still compete for public tenders. A more predictable, cost-reflective framework would restore the confidence needed for capital spending and export growth. Pricing strategies built on multi-year trajectories, rather than annual cliff-edge adjustments, would reduce uncertainty for companies and the National Department of Health.

On the public side, preferential procurement needs explicit budget impact thresholds. Preference margins or local-content scorecards protect capacity only if they leave enough competition to limit price inflation. The National Treasury and payers will need joint scenario models that test net fiscal outcomes over five- to ten-year horizons, counting avoided disruption costs alongside any near-term premium. The SAHPRA work stream matters too: faster, more predictable regulatory timelines lower the cost of maintaining local dossiers and improve ease of doing business against import-reliant competitors.

System dynamics and the data imperative

Once local plants close, the system behaves differently. Reliance on distant supply chains raises exposure to currency swings, shipping delays and global demand spikes. The task force’s emphasis on better data is the practical remedy. Shared, transparent datasets on tender outcomes by value and volume, actual landed costs, employment multipliers and historical stock-out patterns would let negotiations rest on evidence rather than positions. Health technology assessment bodies could then build multi-criteria analysis into routine procurement, weighting security of supply and industrial contribution alongside clinical and budget metrics. A stable South African manufacturing base could anchor continental supply, but only if regulatory efficiency and investment incentives keep pace with international norms. The Presidency has framed the goal as a sustainable, agile and innovative sector. Reaching it depends on turning that intent into measurable changes in tender design and capital formation.

Strategic takeaways for the decade ahead

South Africa’s ability to deliver reliable medicines at scale depends on whether pharma localisation strategy can be made commercially and fiscally coherent. The task force gives health economics, pricing and industrial policy a shared setting in which to be discussed together rather than as competing disciplines. Success would look like stabilised local value shares in key tenders, restored investment signals, shorter regulatory cycles at SAHPRA and measurable gains in supply resilience. Open questions remain: the size of any preference margin, the governance of shared data and the commercial translation of FuturePharma outputs.

Frequently Asked Questions

What does pharma localisation strategy mean for medicine prices in South Africa?

It means balancing short-term affordability with long-term supply security. A well-designed approach can prevent hidden costs from stock-outs or currency shocks while still keeping patient prices in check through smarter tender design and total-cost-of-ownership models.

How can companies prepare evidence for the new task force?

Focus on data that shows employment multipliers, skills retention and reduced supply risk. Present hybrid procurement models that combine competitive pricing with clear local-content commitments, and use multi-year pricing trajectories to restore investment confidence.

Will preferential procurement raise costs for the National Health Insurance?

Not if it is calibrated correctly. Joint scenario modelling between National Treasury and payers can test five- to ten-year outcomes, including avoided disruption costs, so any short-term premium is weighed against measurable gains in resilience and domestic economic contribution.